Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENOVID-E 21 vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norethindrone is a progestin that suppresses gonadotropin release, inhibiting ovulation; mestranol is an estrogen that stabilizes endometrium and provides cycle control.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Treatment of moderate to severe acne vulgaris in females ≥15 years of age without known contraindications to oral contraceptive therapy,Oral contraception
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet (norethynodrel 2.5 mg, mestranol 0.1 mg) orally once daily for 21 consecutive days, followed by 7 days without medication. Repeat cycle.
400 mg orally once daily with food.
Terminal elimination half-life: 27–36 hours (mean 30.8 h). Steady-state reached after 5–7 days. Clinical context: allows once-daily dosing with stable estrogenic effect.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Norethindrone: primarily hepatic via reduction and conjugation (CYP3A4 minor). Mestranol: demethylated to ethinyl estradiol; further metabolized by CYP3A4.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
73% renal (45% as unchanged norethindrone, 20% as conjugates, 8% as other metabolites), 27% fecal via bile. Enterohepatic recirculation accounts for 15% of total clearance.
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Norethindrone: 61% bound to albumin, 36% to SHBG (sex hormone-binding globulin). Ethinylestradiol: 97–98% bound (mainly albumin). Total protein binding for norethindrone: 97%.
98% bound to albumin
Norethindrone: Vd 3.6–4.5 L/kg (mean 4.0 L/kg). Ethinylestradiol: Vd 2.5–3.6 L/kg (mean 3.1 L/kg). Clinical meaning: extensive distribution into tissues, including breast, adipose, and reproductive organs.
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: norethindrone 50–73% (first-pass effect reduces absolute bioavailability); ethinylestradiol 38–48% (first-pass metabolism in gut wall and liver).
Oral: 85-90%; IM: 95-100%
No specific guidelines; use with caution in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to potential fluid retention.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution and monitor liver function; no specific dose adjustment established.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Not approved for use in pediatric patients; safety and efficacy not established.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for postmenopausal women; avoid use due to increased risk of thromboembolic events and cardiovascular disease.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases risk of serious cardiovascular side effects from oral contraceptive use. Risk increases with age and smoking ≥15 cigarettes per day. Women over 35 who smoke should not use this product.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Increased risk of thromboembolic disorders; discontinue if jaundice, visual disturbances, or migraine occurs; may cause fluid retention; monitor blood pressure; exacerbation of depression; liver enzyme alterations; glucose intolerance; cases of breakthrough bleeding; use with caution in patients with renal impairment.
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Thrombophlebitis or thromboembolic disorders; history of deep vein thrombosis or pulmonary embolism; cerebrovascular or coronary artery disease; known or suspected breast cancer; estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; pregnancy; known or suspected pregnancy; liver tumors or active liver disease; hypersensitivity to any component.
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No specific food restrictions. However, grapefruit juice may increase estrogen exposure and side effects; limit intake. Caffeine metabolism may be reduced, leading to increased caffeine effects.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
First trimester: Increased risk of cardiovascular defects and neural tube defects; second and third trimesters: Risk of feminization of male fetus, urogenital abnormalities, and potential long-term metabolic effects.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Contraindicated during breastfeeding. Estrogens and progestins are excreted in breast milk with an M/P ratio approximately 0.5 for norethynodrel and mestranol. May reduce milk production and alter composition.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
No dose adjustment is recommended; use in pregnancy is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased clearance) may reduce efficacy if used inadvertently, but no formal adjustments are established.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
ENOVID-E 21 is a combined oral contraceptive containing mestranol and norethynodrel. It must be taken at the same time daily. Monitor for thromboembolic events, especially in smokers over 35. Use with caution in patients with history of depression, migraine, or liver disease. Breakthrough bleeding may occur in the first few cycles.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one tablet daily at the same time, in the order directed. Do not skip doses.,Missed pills increase pregnancy risk; if one pill is missed, take it as soon as remembered, then continue. If two or more are missed, use backup contraception.,Common side effects include nausea, headache, breast tenderness, and irregular bleeding, which often improve after a few cycles.,Seek medical attention for signs of blood clot: sudden chest pain, shortness of breath, leg pain or swelling, vision changes, or severe headache.,Smoking while on this pill increases risk of serious cardiovascular side effects; avoid smoking.,This pill does not protect against HIV or other sexually transmitted infections; use condoms for STI prevention.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENOVID-E 21 vs ADQUEY, answered by our medical review team.
ENOVID-E 21 is a Oral Contraceptive that works by Norethindrone is a progestin that suppresses gonadotropin release, inhibiting ovulation; mestranol is an estrogen that stabilizes endometrium and provides cycle control.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENOVID-E 21 and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENOVID-E 21 is: One tablet (norethynodrel 2.5 mg, mestranol 0.1 mg) orally once daily for 21 consecutive days, followed by 7 days without medication. Repeat cycle.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENOVID-E 21 and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENOVID-E 21 is classified as Category C. First trimester: Increased risk of cardiovascular defects and neural tube defects; second and third trimesters: Risk of feminization of male fetus, urogenital abnormalities, and po. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.